{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T16:05:58Z","timestamp":1784909158571,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004541","name":"Ministry of Education, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007488","name":"Indian Institute of Technology Delhi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007488","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.nano.2022.102627","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T16:24:53Z","timestamp":1669047893000},"page":"102627","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Polylactic acid based polymeric nanoparticle mediated co-delivery of navitoclax and decitabine for cancer therapy"],"prefix":"10.1016","volume":"47","author":[{"given":"Neha","family":"Mehrotra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd","family":"Anees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachchidanand","family":"Tiwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surender","family":"Kharbanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harpal","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nano.2022.102627_bb0005","series-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","first-page":"209","volume":"71(3)","author":"Sung","year":"2021"},{"issue":"3","key":"10.1016\/j.nano.2022.102627_bb0010","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s11912-022-01199-y","article-title":"Targeting apoptosis in cancer","volume":"24","author":"Singh","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.nano.2022.102627_bb0015","series-title":"Combination Therapy in Metastatic Hormone-sensitive Prostate Cancer: Is Three a Crowd?","volume":"14","author":"Davis","year":"2022"},{"key":"10.1016\/j.nano.2022.102627_bb0020","series-title":"High Drug-Loading Nanomedicines for Tumor Chemo\u2013Photo Combination Therapy: Advances and Perspectives","first-page":"1735","volume":"14(8)","author":"Wang","year":"2022"},{"issue":"1","key":"10.1016\/j.nano.2022.102627_bb0025","doi-asserted-by":"crossref","first-page":"2120676","DOI":"10.1080\/2162402X.2022.2120676","article-title":"Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness","volume":"11","author":"Barnestein","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.nano.2022.102627_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2022.100103","article-title":"New paradigm in combination therapy of siRNA with chemotherapeutic drugs for effective cancer therapy","volume":"3","author":"Kumar","year":"2022","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"10.1016\/j.nano.2022.102627_bb0035","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jconrel.2019.03.015","article-title":"Threatening cancer with nanoparticle aided combination oncotherapy","volume":"301","author":"Rawal","year":"2019","journal-title":"J Control Release"},{"issue":"1","key":"10.1016\/j.nano.2022.102627_bb0040","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.nano.2022.102627_bb0045","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/cdd.2015.50","article-title":"The BCL-2 protein family, BH3-mimetics and cancer therapy","volume":"22","author":"Delbridge","year":"2015","journal-title":"Cell Death Differ"},{"issue":"1","key":"10.1016\/j.nano.2022.102627_bb0050","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1517\/14728222.2013.733001","article-title":"Targeting the Bcl-2 family for cancer therapy","volume":"17","author":"Thomas","year":"2013","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.nano.2022.102627_bb0055","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jconrel.2016.06.012","article-title":"Nanomedicine of synergistic drug combinations for cancer therapy\u2013strategies and perspectives","volume":"240","author":"Zhang","year":"2016","journal-title":"J Control Release"},{"issue":"7","key":"10.1016\/j.nano.2022.102627_bb0060","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20212051","article-title":"Emerging concepts in designing next-generation multifunctional nanomedicine for cancer treatment","volume":"42","author":"Chakraborty","year":"2022","journal-title":"Biosci. Rep"},{"issue":"9","key":"10.1016\/j.nano.2022.102627_bb0065","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.nano.2022.102627_bb0070","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00280-014-2530-9","article-title":"Mechanism-based pharmacokinetic\/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia","volume":"74","author":"Kaefer","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.nano.2022.102627_bb0075","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/15384047.2015.1108485","article-title":"Combination with vorinostat overcomes ABT-263 (navitoclax) resistance of small cell lung cancer","volume":"17","author":"Nakajima","year":"2016","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.nano.2022.102627_bb0080","series-title":"Combination Therapy of Navitoclax With Chemotherapeutic Agents in Solid Tumors and Blood Cancer: A Review of Current Evidence","first-page":"1353","volume":"13(9)","author":"Nor Hisam","year":"2021"},{"issue":"6","key":"10.1016\/j.nano.2022.102627_bb0085","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/s41375-018-0327-2","article-title":"Dasatinib and navitoclax act synergistically to target NUP98-NSD1(+)\/FLT3-ITD(+) acute myeloid leukemia","volume":"33","author":"Kivioja","year":"2019","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.nano.2022.102627_bb0090","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.3109\/10428194.2015.1030638","article-title":"A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia","volume":"56","author":"Kipps","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.nano.2022.102627_bb0095","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1038\/leu.2014.44","article-title":"BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies","volume":"28","author":"Bogenberger","year":"2014","journal-title":"Leukemia"},{"issue":"14","key":"10.1016\/j.nano.2022.102627_bb0100","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1158\/0008-5472.CAN-14-2860","article-title":"KRAS genomic status predicts the sensitivity of ovarian cancer cells to decitabine","volume":"75","author":"Stewart","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.nano.2022.102627_bb0105","series-title":"Epigenetic Cancer Therapy","first-page":"525","article-title":"Chapter 23 - clinical trials","author":"Zhu","year":"2015"},{"issue":"1","key":"10.1016\/j.nano.2022.102627_bb0110","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2217\/epi.09.44","article-title":"Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors","volume":"2","author":"Cowan","year":"2010","journal-title":"Epigenomics"},{"issue":"7","key":"10.1016\/j.nano.2022.102627_bb0115","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/0006-2952(83)90293-9","article-title":"Kinetics of deamination of 5-aza-2'-deoxycytidine and cytosine arabinoside by human liver cytidine deaminase and its inhibition by 3-deazauridine, thymidine or uracil arabinoside","volume":"32","author":"Chabot","year":"1983","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.nano.2022.102627_bb0120","series-title":"Size-controlled Nanomicelles of Poly (Lactic Acid)\u2013Poly (Ethylene Glycol) Copolymers With a Multiblock Configuration","first-page":"1177","volume":"7(6)","author":"Somekawa","year":"2015"},{"key":"10.1016\/j.nano.2022.102627_bb0125","series-title":"Dependence of Morphology on Composition of Poly (L-lactide)\u2013Poly (Ethylene Glycol) Multiblock Copolymers","first-page":"233","volume":"13(3-4)","author":"Luo","year":"2002"},{"key":"10.1016\/j.nano.2022.102627_bb0130","series-title":"Synthesis and Properties of Poly (L-lactide)-Poly (Ethylene Glycol) Multiblock Copolymers by Coupling Triblock Copolymers","first-page":"245","volume":"14(3-5)","author":"Chen","year":"2003"},{"key":"10.1016\/j.nano.2022.102627_bb0135","series-title":"Poly(lactic acid)\/Poly(ethylene glycol) Polymer Nanocomposites: Effects of Graphene Nanoplatelets","first-page":"93","volume":"6(1)","author":"Chieng","year":"2014"},{"issue":"8","key":"10.1016\/j.nano.2022.102627_bb0140","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1021\/nl0805615","article-title":"Method for analysis of nanoparticle hemolytic properties in vitro","volume":"8","author":"Dobrovolskaia","year":"2008","journal-title":"Nano Lett"},{"issue":"7","key":"10.1016\/j.nano.2022.102627_bb0145","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/rcm.2423","article-title":"Characterization of Decomposition Products and Preclinical and Low Dose Clinical Pharmacokinetics of Decitabine (5-Aza-2\u2032-deoxycytidine) by a New Liquid Chromatography\/tandem Mass Spectrometry Quantification Method","volume":"20","author":"Liu","year":"2006","journal-title":"Rapid Com Mass Spec"},{"key":"10.1016\/j.nano.2022.102627_bb0150","series-title":"Small Molecules in Oncology","first-page":"269","article-title":"Decitabine","author":"Hackanson","year":"2014"},{"issue":"11","key":"10.1016\/j.nano.2022.102627_bb0155","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1158\/1078-0432.CCR-14-2506","article-title":"Elucidation of acquired resistance to Bcl-2 and MDM2 inhibitors in acute leukemia in vitro and in vivo","volume":"21","author":"Hoffman-Luca","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"13","key":"10.1016\/j.nano.2022.102627_bb0160","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-19-1900","article-title":"5-azacitidine induces NOXA to prime AML cells for venetoclax-mediated apoptosis","volume":"26","author":"Jin","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.nano.2022.102627_bb0165","article-title":"Clinical review: navitoclax as a pro-apoptotic and anti-fibrotic agent","volume":"26","author":"Mohamad Anuar","year":"2020","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.nano.2022.102627_bb0170","doi-asserted-by":"crossref","first-page":"16078","DOI":"10.1038\/ncomms16078","article-title":"Targeting the differential addiction to anti-apoptotic BCL2 family for cancer therapy","volume":"8","author":"Inoue-Yamauchi","year":"2017","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.nano.2022.102627_bb0175","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2010.31.6208","article-title":"Phase I study of navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors","volume":"29","author":"Gandhi","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.nano.2022.102627_bb0180","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1158\/1535-7163.MCT-19-0745","article-title":"Decitabine response in breast cancer requires efficient drug processing and is not limited by multidrug resistance","volume":"19","author":"Dahn","year":"2020","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.nano.2022.102627_bb0185","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2217\/epi.09.44","article-title":"Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors","volume":"2","author":"Cowan","year":"2010","journal-title":"Epigenomics"},{"issue":"12","key":"10.1016\/j.nano.2022.102627_bb0190","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1158\/1535-7163.MCT-11-0415","article-title":"The Bcl-2\/Bcl-X(L)\/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo","volume":"10","author":"Chen","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"10.1016\/j.nano.2022.102627_bb0195","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1073\/pnas.1104778108","article-title":"Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737","volume":"109","author":"Oakes","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.nano.2022.102627_bb0200","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ccr.2013.06.002","article-title":"Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer","volume":"24","author":"Vaillant","year":"2013","journal-title":"Cancer Cell"}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963422001137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963422001137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:19:21Z","timestamp":1761549561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1549963422001137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":40,"alternative-id":["S1549963422001137"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2022.102627","relation":{},"ISSN":["1549-9634"],"issn-type":[{"value":"1549-9634","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Polylactic acid based polymeric nanoparticle mediated co-delivery of navitoclax and decitabine for cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Nanomedicine: Nanotechnology, Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nano.2022.102627","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102627"}}